334.75 USD
-0.08 (-0.02%)
334.8 USD
+0.05 (+0.01%)
Taking everything into account, SWAV scores 6 out of 10 in our fundamental rating. SWAV was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While SWAV has a great health rating, its profitability is only average at the moment. SWAV is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make SWAV a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year SWAV was profitable.
In the past year SWAV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
In multiple years SWAV reported negative operating cash flow during the last 5 years.
1.2 Ratios
SWAV's Return On Assets of 9.95% is amongst the best of the industry. SWAV outperforms 93.23% of its industry peers.
The Return On Equity of SWAV (21.76%) is better than 95.31% of its industry peers.
SWAV's Return On Invested Capital of 8.81% is amongst the best of the industry. SWAV outperforms 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of SWAV (20.76%) is better than 94.79% of its industry peers.
SWAV's Operating Margin of 20.52% is amongst the best of the industry. SWAV outperforms 94.27% of its industry peers.
The Gross Margin of SWAV (86.99%) is better than 96.35% of its industry peers.
In the last couple of years the Gross Margin of SWAV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SWAV is destroying value.
The number of shares outstanding for SWAV has been increased compared to 1 year ago.
The number of shares outstanding for SWAV has been increased compared to 5 years ago.
The debt/assets ratio for SWAV is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 10.26, SWAV belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
SWAV's Debt to FCF ratio of 4.41 is amongst the best of the industry. SWAV outperforms 82.81% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that SWAV is somewhat dependend on debt financing.
SWAV has a worse Debt to Equity ratio (0.97) than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
A Current Ratio of 13.81 indicates that SWAV has no problem at all paying its short term obligations.
SWAV has a Current ratio of 13.81. This is amongst the best in the industry. SWAV outperforms 97.92% of its industry peers.
SWAV has a Quick Ratio of 12.61. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.61, SWAV belongs to the best of the industry, outperforming 97.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.34% over the past year.
SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.44%.
The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
Based on estimates for the next years, SWAV will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.56% on average per year.
Based on estimates for the next years, SWAV will show a very strong growth in Revenue. The Revenue will grow by 20.10% on average per year.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 78.21, which means the current valuation is very expensive for SWAV.
Based on the Price/Earnings ratio, SWAV is valued a bit cheaper than 67.19% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.59. SWAV is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 53.09 indicates a quite expensive valuation of SWAV.
68.75% of the companies in the same industry are more expensive than SWAV, based on the Price/Forward Earnings ratio.
SWAV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.80.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SWAV is valued a bit cheaper than the industry average as 67.19% of the companies are valued more expensively.
SWAV's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of SWAV may justify a higher PE ratio.
SWAV's earnings are expected to grow with 24.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. Dividend
5.1 Amount
SWAV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | 15.95 | ||
| P/FCF | 75.65 | ||
| P/OCF | 63.5 | ||
| P/B | 16.72 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 66.43 |
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | 10.42% | ||
| ROIC | 8.81% | ||
| ROICexc | 26.17% | ||
| ROICexgc | 34.98% | ||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM | 21.08% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 270.11% | ||
| Cap/Sales | 4.03% | ||
| Interest Coverage | 30.21 | ||
| Cash Conversion | 114.09% | ||
| Profit Quality | 101.56% | ||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z | 10.26 |
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A
SHOCKWAVE MEDICAL INC / SWAV FAQ
What is the fundamental rating for SWAV stock?
ChartMill assigns a fundamental rating of 6 / 10 to SWAV.
What is the valuation status of SHOCKWAVE MEDICAL INC (SWAV) stock?
ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.
What is the profitability of SWAV stock?
SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for SWAV stock?
The Price/Earnings (PE) ratio for SHOCKWAVE MEDICAL INC (SWAV) is 78.21 and the Price/Book (PB) ratio is 16.72.
Can you provide the financial health for SWAV stock?
The financial health rating of SHOCKWAVE MEDICAL INC (SWAV) is 7 / 10.